Market Research Logo

Hodgkin Lymphoma - Pipeline Review, H1 2015

Hodgkin Lymphoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Hodgkin Lymphoma - Pipeline Review, H1 2015’, provides an overview of the Hodgkin Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Hodgkin Lymphoma Overview
Therapeutics Development
Pipeline Products for Hodgkin Lymphoma - Overview
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis
Hodgkin Lymphoma - Therapeutics under Development by Companies
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
Hodgkin Lymphoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hodgkin Lymphoma - Products under Development by Companies
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
Hodgkin Lymphoma - Companies Involved in Therapeutics Development
4SC AG
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Affimed Therapeutics AG
Aptose Biosciences Inc.
AVEO Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Constellation Pharmaceuticals, Inc.
Dynavax Technologies Corporation
Gamida Cell Ltd.
Incyte Corporation
Johnson & Johnson
MABLife S.A.S
Merck & Co., Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pharmacyclics, Inc.
Philogen S.p.A.
Seattle Genetics, Inc.
Sigma-Tau S.p.A.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Syndax Pharmaceuticals, Inc.
Takeda Oncology
Tekmira Pharmaceuticals Corp.
TG Therapeutics, Inc.
Hodgkin Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abexinostat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AFM-13 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APTO-253 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-986016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target CD30 for Relapsed and Refractory Lymphomas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPI-0610 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
entinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ferritarg - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ficlatuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iomab-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-40346527 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LMP-400 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LMP-776 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDX-1401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NiCord - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nivolumab (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSC-678515 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panobinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pevonedistat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
procarbazine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radretumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
resminostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ricolinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP-5264 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SD-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
StemEx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TKM-PLK1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vinorelbine tartrate liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hodgkin Lymphoma - Recent Pipeline Updates
Hodgkin Lymphoma - Dormant Projects
Hodgkin Lymphoma - Discontinued Products
Hodgkin Lymphoma - Product Development Milestones
Featured News & Press Releases
Dec 09, 2014: Affimed Presents Final Data for AFM13 Phase 1 Trial at ASH
Dec 08, 2014: Seattle Genetics Highlights Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting
Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Dec 06, 2014: Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma
Dec 06, 2014: Data Investigating KEYTRUDA (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting
Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014
Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting
Oct 13, 2014: Takeda’s Adcetri (brentuximab vedotin) is the first ultra-orphan medicine to be accepted by the SMC via the new assessment process
Sep 29, 2014: Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma
Sep 26, 2014: Seattle Genetics to Host Conference Call and Webcast on September 29, 2014 Regarding Top-line Data from ADCETRIS (brentuximab vedotin) Phase 3 AETHERA Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hodgkin Lymphoma, H1 2015
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2015
Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2015
Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc., H1 2015
Hodgkin Lymphoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2015
Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2015
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2015
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2015
Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2015
Hodgkin Lymphoma - Pipeline by MABLife S.A.S, H1 2015
Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2015
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015
Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2015
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2015
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015
Hodgkin Lymphoma - Pipeline by Takeda Oncology, H1 2015
Hodgkin Lymphoma - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015
Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015
Hodgkin Lymphoma - Dormant Projects, H1 2015
Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2015
Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2015
Hodgkin Lymphoma - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Hodgkin Lymphoma, H1 2015
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report